Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
3d rendered HIV Virus in Blood Stream in color background

Results from the RIVER (Research in Viral Eradication of HIV Reservoirs) study, the first ever randomised clinical trial to test the ‘kick and kill’ approach to curing HIV, were published in The Lancet this week. Although the results were not what the researchers hoped for, the study clearly highlights the new direction that HIV research is heading. The trial, funded by the Medical Research Council, was a major collaboration between Oxford University, Imperial College and the MRC Clinical Trials Unit and was run by CHERUB (Collaborative HIV Eradication of Reservoirs UK BRC), an NIHR cooperative of clinicians, researchers and patients working together to find a cure for HIV.

Researchers used the drug Vorinostat to try and wake up dormant HIV hiding in CD4 T Cells (the ‘kick’) in conjunction with vaccine-stimulated CD8 T cells to enact the ‘kill’. The vaccine had been made in Oxford by a team led by Prof Tomas Hanke. The aim was to see if they could reduce the amount of HIV in the ‘latent reservoir’ – the source of persistent, dormant HIV that means the infection can’t be cured and current therapy needs to be taken for life. Although there was evidence that each individual step had worked, the trial was unable to show an impact on the size of the HIV reservoir.

Professor John Frater of the Nuffield Department of Medicine is a senior author and the Oxford NIHR BRC lead for CHERUB commented: “It is clearly disappointing that we didn’t see the result we hoped for in RIVER, but this is a landmark moment in HIV research as it marks a new era of investment in major clinical trials testing novel approaches to achieve an HIV cure. Participant engagement was incredible – this was a complex study and yet almost no visits were missed, showing how engaged the community of those living with HIV are in this sort of research. For many people living with HIV, current antiretroviral therapy is life changing but can be linked with toxicity, resistance and stigma. There has always been an aspiration for an HIV cure and although this is still a long way off – as RIVER shows – our study demonstrates that there is engagement and momentum in the research community and hope for the millions living with HIV.”

Read the full paper, published in The Lancet

Similar stories

Human challenge trial launches to study immune response to COVID-19

Clinical Trials Coronavirus COVID-19 General

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.